Identification of low molecular weight pyroglutamate A{beta} oligomers in Alzheimer disease: a novel tool for therapy and diagnosis - Wikidata - awgldk - TriplyDB

Identification of low molecular weight pyroglutamate A{beta} oligomers in Alzheimer disease: a novel tool for therapy and diagnosis

Identification of low molecular weight pyroglutamate A{beta} oligomers in Alzheimer disease: a novel tool for therapy and diagnosis

http://www.wikidata.org/entity/Q30497751

about

Immunotherapy targeting pyroglutamate-3 Aβ: prospects and challenges Immunotherapy for Alzheimer's disease: hoops and hurdles Alzheimer's disease--a panorama glimpse Galantamine slows down plaque formation and behavioral decline in the 5XFAD mouse model of Alzheimer's disease.Purification and Characterization of Recombinant N-Terminally Pyroglutamate-Modified Amyloid-β Variants and Structural Analysis by Solution NMR Spectroscopy Structural Analysis and Aggregation Propensity of Pyroglutamate Aβ(3-40) in Aqueous Trifluoroethanol Enhanced Fibril Fragmentation of N-Terminally Truncated and Pyroglutamyl-Modified Aβ Peptides.An anti-pyroglutamate-3 Aβ vaccine reduces plaques and improves cognition in APPswe/PS1ΔE9 mice Cortical pyroglutamate amyloid-β levels and cognitive decline in Alzheimer's disease.Pyroglutamate amyloid β (Aβ) aggravates behavioral deficits in transgenic amyloid mouse model for Alzheimer disease.Synaptic deficits in layer 5 neurons precede overt structural decay in 5xFAD mice.Focusing the amyloid cascade hypothesis on N-truncated Abeta peptides as drug targets against Alzheimer's disease Pyroglutamate-amyloid-β and glutaminyl cyclase are colocalized with amyloid-β in secretory vesicles and undergo activity-dependent, regulated secretion.Disturbed Ca2+ homeostasis increases glutaminyl cyclase expression; connecting two early pathogenic events in Alzheimer's disease in vitro.Detection of peri-synaptic amyloid-β pyroglutamate aggregates in early stages of Alzheimer's disease and in AβPP transgenic mice using a novel monoclonal antibody Pyroglutamate amyloid-β (Aβ): a hatchet man in Alzheimer disease Hyperphosphorylated tau in young and middle-aged subjects.Pyroglutamate-Aβ 3 and 11 colocalize in amyloid plaques in Alzheimer's disease cerebral cortex with pyroglutamate-Aβ 11 forming the central core.Neuron loss in the 5XFAD mouse model of Alzheimer's disease correlates with intraneuronal Aβ42 accumulation and Caspase-3 activation.Abundant pyroglutamate-modified ABri and ADan peptides in extracellular and vascular amyloid deposits in familial British and Danish dementias.Intracellular accumulation of aggregated pyroglutamate amyloid beta: convergence of aging and Aβ pathology at the lysosome Passive immunization against pyroglutamate-3 amyloid-β reduces plaque burden in Alzheimer-like transgenic mice: a pilot study.Comprehensive behavioral characterization of an APP/PS-1 double knock-in mouse model of Alzheimer's disease pGluAβ increases accumulation of Aβ in vivo and exacerbates its toxicity.N-truncated Abeta starting with position four: early intraneuronal accumulation and rescue of toxicity using NT4X-167, a novel monoclonal antibody.A modification-specific peptide-based immunization approach using CRM197 carrier protein: Development of a selective vaccine against pyroglutamate Aβ peptides.Amyloid β-protein oligomers and Alzheimer's disease.Intraneuronal Aβ as a trigger for neuron loss: can this be translated into human pathology?Protein engineering to stabilize soluble amyloid β-protein aggregates for structural and functional studies.Pyroglutamate-Modified Amyloid Beta Peptides: Emerging Targets for Alzheimer´s Disease Immunotherapy.Phosphorylation of the amyloid β-peptide at Ser26 stabilizes oligomeric assembly and increases neurotoxicity.Characterization of AD-like phenotype in aged APPSwe/PS1dE9 mice.Pyroglutamylated amyloid-β peptide reverses cross β-sheets by a prion-like mechanism.APP/Aβ structural diversity and Alzheimer's disease pathogenesis.Structural and functional analyses of pyroglutamate-amyloid-β-specific antibodies as a basis for Alzheimer immunotherapy.Unmodified and pyroglutamylated amyloid β peptides form hypertoxic hetero-oligomers of unique secondary structure.Pyroglutamate and Isoaspartate modified Amyloid-Beta in ageing and Alzheimer's disease.Endothelial LRP1 - A Potential Target for the Treatment of Alzheimer's Disease : Theme: Drug Discovery, Development and Delivery in Alzheimer's Disease Guest Editor: Davide Brambilla.A Multifunctional Biocompatible Drug Candidate is Highly Effective in Delaying Pathological Signs of Alzheimer's Disease in 5XFAD Mice.Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against N‑truncated Abeta in sporadic Alzheimer disease cases and mouse models.

P2860

Q26745928-554677AE-361A-4928-87BD-9B1EE540780C Q26823877-1921A2C8-DB49-4224-9CC6-2BA9020BFCD3 Q27011749-69207B5C-CD87-4F40-B1F8-08E4316B655E Q28540060-67201CCC-9F01-4870-B928-CD44B77D9E6C Q28550062-9CEBEB7C-CCDF-4DAD-9EB0-3364493C3489 Q28551142-034406FA-F474-4E34-BA21-D09227CF1968 Q30315438-CA96220B-8F00-422B-A395-4657FB87E7FC Q30316057-5379740E-2641-4A3A-A029-31F658F8CDDC Q30361851-4B1BDA87-DA40-44FE-9377-92E1E0153802 Q30512697-E6AAC655-C07E-4FA3-BEF8-71BFCB5E4915 Q30582501-639B2773-0360-4153-99A4-0D9D2E11802B Q33624303-7B4C4548-E478-4EDE-9359-8F080784DB1A Q34076284-9F55122D-724E-4F88-9AB8-C5F07AC0C2FD Q34412693-A0FA6D0A-7C77-4762-BEEA-BA7813BE4ADD Q35151492-663FC9AE-27D6-40FE-B6A5-FFF584C33EE3 Q35604177-18DFA87A-CF1C-438C-8501-5CE37103CFF2 Q35644063-EC8EF08D-FCD0-4CD5-82F6-45C505EECF36 Q35660682-B7A8D63E-839F-4415-890E-7B7D927617DE Q36556213-113DAE9F-BD98-462D-9CC9-49F6E3CD12CF Q36605288-7D6C6046-B3C2-4A02-8463-6DDF0A611212 Q36795149-4BB19F51-28C6-466A-B712-11BFB1CAE019 Q36984142-3A36253E-65CA-4F3E-89ED-90E19E5EB51D Q36997908-6418EB82-2940-4441-AE86-51452059F38B Q37322106-C6D3E41A-DAE4-4C5D-B787-219D467CE4D7 Q37485472-484487A5-987C-4A11-AA87-759F95F008BE Q37604055-127171AB-2B3C-4228-94F9-0DBDF087A5D3 Q37690332-62FD8DD1-84C5-4D3A-ADC0-5B63BE0D4417 Q37905118-AA17DDDA-101E-4DFC-8436-8E0617182133 Q37913546-F006107E-B8CD-4E58-98BF-169778833E83 Q38176899-E54BD439-1173-4F52-8914-10F543D97114 Q38959054-AE5F7832-EEED-47E6-8613-DD84B75BAD1E Q41444056-32748238-540F-48E3-BE28-E50AE24FAB01 Q42212510-B703FA5A-8791-483D-8E38-AECDDBA18406 Q46320596-CBD67CEF-C74B-4E2F-8ACA-3A57B7314438 Q46348872-C6C34B44-6425-4AC8-90F6-72C84ECCB985 Q46404042-BE69D25A-C3E5-486A-9F36-FADBC006E033 Q47133483-7B5481E1-81E2-4379-B2E9-FDD8A7ADE288 Q47743028-A5000794-0DD7-41CE-B0D2-C22E888DDF11 Q50585752-52834FED-528E-4A77-9911-3A840E73A863 Q53311356-935806AA-B1D0-4F1D-BD7E-05CFF56C142D

P2860

Identification of low molecular weight pyroglutamate A{beta} oligomers in Alzheimer disease: a novel tool for therapy and diagnosis

http://www.wikidata.org/entity/Q30497751

description

2010 nî lūn-bûn

@nan

2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Identification of low molecula ...... tool for therapy and diagnosis

@ast

Identification of low molecula ...... tool for therapy and diagnosis

@en

type

label

Identification of low molecula ...... tool for therapy and diagnosis

@ast

Identification of low molecula ...... tool for therapy and diagnosis

@en

prefLabel

Identification of low molecula ...... tool for therapy and diagnosis

@ast

Identification of low molecula ...... tool for therapy and diagnosis

@en

P1433

Q30497751-1055AB2E-8DE3-4F5D-806B-7E961C320D10

P1476

Q30497751-7F009A13-51E7-43FB-83D6-C878657D4A4B

P2093

Q30497751-0C196EEE-BAA1-49DC-A86B-8224BD045950

Q30497751-0E217B20-6912-4F46-84C8-CF0D2FDED39C

Q30497751-1617A6F1-5EA2-4C62-829A-E51305F36380

Q30497751-26D558A9-5671-4DC0-80CD-4D8868F30998

Q30497751-2F02377D-73C8-475E-8637-B90C38498E0A

Q30497751-41F064D5-B2CA-4895-8C6C-BA0E2F9C5ECF

Q30497751-42955BC7-B687-439A-81C3-1F5BC39B43E8

Q30497751-5A41E651-05F3-4D92-AFDA-049A7130553F

Q30497751-74CF33B6-041B-41A8-8860-078E802110A4

Q30497751-873742F6-4215-4827-8A0E-70FAF78B06E0

P2860

Q30497751-00B7D5D8-043D-4B3A-97BB-21B11D100278

Q30497751-03C69BB1-F09D-40AD-8FC6-3C41333E6806

Q30497751-09ADD2B9-171B-46D4-95D9-4FDE09AC013C

Q30497751-13CE180E-B67E-4031-8B36-612E9ECCFA83

Q30497751-187D2BCA-5D5F-4835-AA4A-3FCCB60E5680

Q30497751-1D03314B-055A-4BF4-BFA0-ED9749A5289A

Q30497751-1E8FD8D7-E45C-4E64-A727-74CA6A3AEB3B

Q30497751-2183D3B8-20E3-42AA-88F7-D0FD93B08941

Q30497751-24392444-1184-4CBC-845C-62D5116A49D5

Q30497751-4220AA88-1069-4A3D-912B-04B597D3AC4B

P304

Q30497751-3D8A30D5-D3C5-495C-95D4-C6A7E07BD3C2

P31

Q30497751-55C7B613-A729-4CFA-93AD-A983437A0D87

P356

Q30497751-BAEA5017-C45D-4EB0-9FED-8B7873786B32

P407

Q30497751-418F0D60-903F-4587-B9F7-AD5E5EC0F688

P433

Q30497751-10139E4F-B6AB-4E52-8B44-AE157F63F752

P478

Q30497751-BBACA213-AAF3-4026-A35C-7612E3FEC695

P50

Q30497751-4EEDEFEE-F06A-44C5-85DD-C4C6FC6A4226

Q30497751-B6ABCEB0-C93C-4D7D-B9A5-5C99E2125DCE

P577

Q30497751-12490266-ED27-402B-B211-07A125DA43D1

P698

Q30497751-6A7AF9DC-E8E3-40A4-BA1A-DDF367414934

P921

Q30497751-5898AEDD-AF9D-4A51-A8EE-31242B207DFF

P932

Q30497751-CE486371-D1BE-40A0-BA43-8EF844426F02

P356

JBC.M110.178707

P1433

Journal of Biological Chemistry

P1476

Identification of low molecula ...... tool for therapy and diagnosis

@en

P2093

Anja Harmeier

http://www.w3.org/2001/XMLSchema#string

Christian Erck

http://www.w3.org/2001/XMLSchema#string

Constanze Geumann

http://www.w3.org/2001/XMLSchema#string

Hannu Kalimo

http://www.w3.org/2001/XMLSchema#string

Henrik Martens

http://www.w3.org/2001/XMLSchema#string

Inge Huitinga

http://www.w3.org/2001/XMLSchema#string

Jochen Walter

http://www.w3.org/2001/XMLSchema#string

Lars Lannfelt

http://www.w3.org/2001/XMLSchema#string

Malin Degerman-Gunnarsson

http://www.w3.org/2001/XMLSchema#string

Oliver Wirths

http://www.w3.org/2001/XMLSchema#string

P2860

A Oligomer-Induced Aberrations in Synapse Composition, Shape, and Density Provide a Molecular Basis for Loss of Connectivity in Alzheimer's Disease

Amyloid plaque core protein in Alzheimer disease and Down syndrome

Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory

Active and passive immunotherapy for neurodegenerative disorders

Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo

Alzheimer's disease: genes, proteins, and therapy

Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway

A specific amyloid-beta protein assembly in the brain impairs memory

Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis

Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins

P304

41517-41524

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1074/JBC.M110.178707

http://www.w3.org/2001/XMLSchema#string

P407

P433

53

http://www.w3.org/2001/XMLSchema#string

P478

285

http://www.w3.org/2001/XMLSchema#string

P50

Martin Ingelsson

P577

2010-10-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20971852

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

3009878

http://www.w3.org/2001/XMLSchema#string